Q-omics provides the consensus-scored IFNB1 profile across patient tissues and cancer cell-line models. IFNB1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IFNB1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, IFNB1 RNA expression shows 8,147 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, HNSC, and LIHC as cancer lineages where IFNB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFNB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFNB1 survival associations across molecular data types. IFNB1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFNB1 RNA expression–survival associations across cancer types. High IFNB1 expression shows unfavorable associations in KIRC, UCEC, KICH, BRCA and HNSC, but favorable associations in OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IFNB1 RNA expression.
This table summarizes IFNB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for IFNB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFNB1 shows lower tumor expression in PAAD and higher tumor expression in HNSC, BRCA, LUAD, CHOL and LUSC. The HNSC box plot shows higher IFNB1 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .012).
This table shows molecular features associated with IFNB1 in patient tissues and cancer cell lines. In patient samples, IFNB1 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, IFNB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BREAST.
